[{"id":"b172bb8d-07dd-4d40-b459-cb7946457b73","acronym":"NRG-BN007","url":"https://clinicaltrials.gov/study/NCT04396860","created_at":"2021-01-18T21:13:04.295Z","updated_at":"2025-02-25T15:34:40.901Z","phase":"Phase 2/3","brief_title":"Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT04396860 - NRG-BN007","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • TMB • IDH1 • MGMT","pipe":" | ","alterations":" PD-L1 expression • MGMT promoter methylation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MGMT promoter methylation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 04/13/2023","primary_completion_date":" 04/13/2023","study_txt":" Completion: 03/11/2025","study_completion_date":" 03/11/2025","last_update_posted":"2025-02-10"},{"id":"fc5b6895-f7f7-4459-b71c-62a35c47f883","acronym":"ProvIDHe","url":"https://clinicaltrials.gov/study/NCT05876754","created_at":"2023-05-25T15:05:46.429Z","updated_at":"2025-02-25T15:20:32.101Z","phase":"Phase 3","brief_title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT05876754 - ProvIDHe","lead_sponsor":"Servier Affaires Médicales","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-10"},{"id":"51b4bfec-34ee-4216-99bf-f5a89c3e2090","acronym":"","url":"https://clinicaltrials.gov/study/NCT04056910","created_at":"2021-01-18T19:53:13.460Z","updated_at":"2025-02-25T14:28:34.351Z","phase":"Phase 2","brief_title":"Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors","source_id_and_acronym":"NCT04056910","lead_sponsor":"Jason J. Luke, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 11/13/2023","primary_completion_date":" 11/13/2023","study_txt":" Completion: 11/13/2023","study_completion_date":" 11/13/2023","last_update_posted":"2025-02-06"},{"id":"254804cf-c50f-409d-b809-0f0a4043dc18","acronym":"CL1-95032-005","url":"https://clinicaltrials.gov/study/NCT05484622","created_at":"2022-08-02T12:55:57.680Z","updated_at":"2025-02-25T16:18:00.683Z","phase":"Phase 1","brief_title":"Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma","source_id_and_acronym":"NCT05484622 - CL1-95032-005","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Voranigo (vorasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 01/20/2023","start_date":" 01/20/2023","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2025-01-14"},{"id":"e68b085a-cda1-45b1-b91f-76f776e1e1a1","acronym":"REGOMA-2","url":"https://clinicaltrials.gov/study/NCT06095375","created_at":"2023-10-23T18:13:31.588Z","updated_at":"2025-02-25T17:26:30.027Z","phase":"Phase 1","brief_title":"Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients","source_id_and_acronym":"NCT06095375 - REGOMA-2","lead_sponsor":"Istituto Oncologico Veneto IRCCS","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Stivarga (regorafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/04/2022","start_date":" 07/04/2022","primary_txt":" Primary completion: 10/09/2024","primary_completion_date":" 10/09/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-12-24"},{"id":"066ab336-a212-45de-9f07-3f558dc780e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02746081","created_at":"2021-01-18T13:27:15.549Z","updated_at":"2025-02-25T17:08:45.816Z","phase":"Phase 1","brief_title":"Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors","source_id_and_acronym":"NCT02746081","lead_sponsor":"Bayer","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY1436032"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 05/26/2016","start_date":" 05/26/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 12/03/2024","study_completion_date":" 12/03/2024","last_update_posted":"2024-12-18"},{"id":"2b8e2f91-c4ad-4a30-bf4b-d41f2c7c9a84","acronym":"INSIGhT","url":"https://clinicaltrials.gov/study/NCT02977780","created_at":"2021-01-18T14:38:25.857Z","updated_at":"2025-02-25T14:36:55.862Z","phase":"Phase 2","brief_title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","source_id_and_acronym":"NCT02977780 - INSIGhT","lead_sponsor":"Patrick Wen, MD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-10-17"},{"id":"bfbf8c75-c7b7-4a8c-ab2c-a6d960bd0ab5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03557359","created_at":"2021-07-05T17:14:56.675Z","updated_at":"2025-02-25T14:27:06.322Z","phase":"Phase 2","brief_title":"Nivolumab for Recurrent or Progressive IDH Mutant Gliomas","source_id_and_acronym":"NCT03557359","lead_sponsor":"Fabio Iwamoto, MD","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-18"},{"id":"f3d782d2-7f3d-4ad2-b8d5-99602c17c34a","acronym":"SONOBIRD","url":"https://clinicaltrials.gov/study/NCT05902169","created_at":"2023-06-13T17:08:12.284Z","updated_at":"2024-07-02T16:34:26.706Z","phase":"Phase 3","brief_title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","source_id_and_acronym":"NCT05902169 - SONOBIRD","lead_sponsor":"CarThera","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • IDH1 R132H • IDH1 R132","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • lomustine"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 01/28/2028","primary_completion_date":" 01/28/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-06-12"},{"id":"450196e9-e0ad-47bf-a736-4b3fdabb7b6e","acronym":"NCI-2019-03057","url":"https://clinicaltrials.gov/study/NCT03953898","created_at":"2021-01-18T19:27:50.729Z","updated_at":"2024-07-02T16:34:37.850Z","phase":"Phase 2","brief_title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","source_id_and_acronym":"NCT03953898 - NCI-2019-03057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"0c02cc4f-da25-44d0-b391-3f1638d91362","acronym":"AMPLIFY-NEOVAC","url":"https://clinicaltrials.gov/study/NCT03893903","created_at":"2021-01-18T19:10:49.432Z","updated_at":"2024-07-02T16:34:38.157Z","phase":"Phase 1","brief_title":"AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma","source_id_and_acronym":"NCT03893903 - AMPLIFY-NEOVAC","lead_sponsor":"German Cancer Research Center","biomarkers":" ATRX","pipe":" | ","alterations":" IDH1 R132","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • IDH1R132H peptide vaccine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/19/2018","start_date":" 10/19/2018","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-05"},{"id":"1b7433f8-fdf4-4ed8-b6bd-286988acbcd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521686","created_at":"2021-01-18T21:39:29.090Z","updated_at":"2024-07-02T16:34:37.926Z","phase":"Phase 1","brief_title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04521686","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"67ee693c-6b97-4b0f-b34b-6654a4861bbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04603001","created_at":"2021-01-19T20:30:51.296Z","updated_at":"2024-07-02T16:34:58.765Z","phase":"Phase 1","brief_title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT04603001","lead_sponsor":"Eli Lilly and Company","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • LY3410738"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/03/2023","primary_completion_date":" 07/03/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-06-05"},{"id":"8420d34e-5720-4abb-8b0f-9d930a4e3baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03212274","created_at":"2021-01-18T15:50:38.215Z","updated_at":"2024-07-02T16:35:02.706Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","source_id_and_acronym":"NCT03212274","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-17"},{"id":"6fd39586-a5ba-42d4-9b04-4797a9ca665f","acronym":"GESTALT","url":"https://clinicaltrials.gov/study/NCT05342883","created_at":"2022-04-25T22:54:38.331Z","updated_at":"2024-07-02T16:35:03.480Z","phase":"Phase 4","brief_title":"GammaTile and Stupp in Newly Diagnosed GBM","source_id_and_acronym":"NCT05342883 - GESTALT","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-15"},{"id":"94267f47-1a52-4bba-b2c5-458f4dbd292b","acronym":"NCI-2018-00921","url":"https://clinicaltrials.gov/study/NCT03471260","created_at":"2021-01-18T17:06:25.544Z","updated_at":"2024-07-02T16:35:06.479Z","phase":"Phase 1/2","brief_title":"Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies","source_id_and_acronym":"NCT03471260 - NCI-2018-00921","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-02"},{"id":"5f9fcf16-f9cb-4521-b187-17cb8a4a4f38","acronym":"2102-HEM-101","url":"https://clinicaltrials.gov/study/NCT02719574","created_at":"2021-01-17T17:25:33.100Z","updated_at":"2024-07-02T16:35:10.352Z","phase":"Phase 1/2","brief_title":"Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation","source_id_and_acronym":"NCT02719574 - 2102-HEM-101","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132 • Chr t(15;17)","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132 • Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • Rezlidhia (olutasidenib)"],"overall_status":"Completed","enrollment":" Enrollment 336","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/28/2023","primary_completion_date":" 12/28/2023","study_txt":" Completion: 01/24/2024","study_completion_date":" 01/24/2024","last_update_posted":"2024-04-10"},{"id":"8458f7b4-ba3b-4835-b691-1de379b3d9f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05921760","created_at":"2023-06-27T14:08:24.970Z","updated_at":"2024-07-02T16:35:10.760Z","phase":"Phase 1/2","brief_title":"Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma","source_id_and_acronym":"NCT05921760","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132C • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132C • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/23/2023","start_date":" 10/23/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-09"},{"id":"ddfe20df-1f45-4bde-9f8e-bac111609114","acronym":"AG120-C-001","url":"https://clinicaltrials.gov/study/NCT02074839","created_at":"2021-01-17T17:36:59.974Z","updated_at":"2024-07-02T16:35:11.311Z","phase":"Phase 1","brief_title":"Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation","source_id_and_acronym":"NCT02074839 - AG120-C-001","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 291","initiation":"Initiation: 03/01/2014","start_date":" 03/01/2014","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-04-05"},{"id":"83026695-d43a-4653-bca6-29f8b4ee5021","acronym":"REVOLUMAB","url":"https://clinicaltrials.gov/study/NCT03925246","created_at":"2021-01-18T19:18:33.109Z","updated_at":"2025-02-25T14:28:20.050Z","phase":"Phase 2","brief_title":"Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas","source_id_and_acronym":"NCT03925246 - REVOLUMAB","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2","pipe":" | ","alterations":" IDH1 mutation • IDH2 mutation • IDH1 R132","tags":["PD-L1 • TMB • IDH1 • IDH2 • MGMT • CD8 • PD-1 • ATRX • CD163 • CD4 • CD68 • FOXP3 • GFAP • OLIG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH2 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • temozolomide"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/30/2019","start_date":" 07/30/2019","primary_txt":" Primary completion: 12/02/2020","primary_completion_date":" 12/02/2020","study_txt":" Completion: 08/18/2021","study_completion_date":" 08/18/2021","last_update_posted":"2024-04-02"},{"id":"8b030438-7eb9-4387-b341-1cc25b72dae1","acronym":"ViCToRy","url":"https://clinicaltrials.gov/study/NCT05609994","created_at":"2022-11-08T14:56:43.419Z","updated_at":"2024-07-02T16:35:13.515Z","phase":"Phase 1","brief_title":"ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas","source_id_and_acronym":"NCT05609994 - ViCToRy","lead_sponsor":"Katy Peters, MD, PhD","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Voranigo (vorasidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-21"},{"id":"5f7d029f-2d49-48f5-8f1d-6627758f9ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030066","created_at":"2021-01-18T14:54:51.381Z","updated_at":"2024-07-02T16:35:14.468Z","phase":"","brief_title":"Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas","source_id_and_acronym":"NCT03030066","lead_sponsor":"Daiichi Sankyo","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e safusidenib (DS-1001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 01/19/2017","start_date":" 01/19/2017","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-15"},{"id":"6053286c-83b6-47bb-9279-55103c8270d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493164","created_at":"2021-01-18T21:35:03.148Z","updated_at":"2024-07-02T16:35:14.734Z","phase":"Phase 2","brief_title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04493164","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-15"},{"id":"95731383-c806-4e36-ace1-c94c54c5626b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03564821","created_at":"2021-01-18T17:32:33.230Z","updated_at":"2024-07-02T16:35:15.543Z","phase":"Phase 1","brief_title":"IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT03564821","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1 • HLA-B","pipe":" | ","alterations":" IDH1 mutation • IDH1 R132","tags":["IDH1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 01/16/2019","start_date":" 01/16/2019","primary_txt":" Primary completion: 05/22/2022","primary_completion_date":" 05/22/2022","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2024-03-08"}]